Phathom Pharmaceuticals to Unveil New GERD Data at ACG 2026
Event summary
- Phathom Pharmaceuticals will present three scientific posters at the ACG 2026 Annual Scientific Meeting, highlighting new data on VOQUEZNA® (vonoprazan) for GERD treatment.
- Presentations include analyses on VOQUEZNA efficacy across BMI subgroups, real-world patient characteristics, and cost-effectiveness compared to PPIs in Erosive Esophagitis.
- The event runs from October 9-14, 2026, in Nashville, Tennessee.
- Phathom will also host a Product Theater to discuss VOQUEZNA’s clinical efficacy and safety profile.
The big picture
Phathom Pharmaceuticals is strategically positioning VOQUEZNA as a next-generation treatment for GERD, challenging the dominance of proton pump inhibitors (PPIs). The company’s focus on real-world data and cost-effectiveness analyses aligns with broader industry trends toward value-based healthcare and personalized medicine. The ACG 2026 presentations could further solidify VOQUEZNA’s role in the GI treatment landscape, particularly if the data supports its use in broader patient populations.
What we're watching
- Clinical Differentiation
- How the new data on VOQUEZNA’s efficacy across BMI subgroups and cost-effectiveness will position it against existing PPIs in the GERD market.
- Market Adoption
- Whether the real-world patient characteristics analysis will accelerate VOQUEZNA’s adoption among GI healthcare providers.
- Regulatory Dynamics
- The pace at which Phathom can leverage these findings to expand VOQUEZNA’s indications or secure additional regulatory approvals.